[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Leeuwenhoek Laboratories Co. Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":112},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,67,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100638212","phase-2-probiotics-for-abemaciclib-induced-abdominal-discomfort-100638212",false,"NCT07605728","Probiotics for Abemaciclib-Induced Abdominal Discomfort.","A Randomized, Phase II Study About Probiotics to Alleviate Abemaciclib-induced Abdominal Discomfort Under Standard Anti-diarrhea Drug Loperamide and Changes of Metabolic Factors in Blood.","Inclusion Criteria:\n\nA. Adults with hormone receptor-positive (HR+) early breast cancer were confirmed.\n\nB. At least 18 years old at the time of signing the informed consent. C. Candidates for adjuvant endocrine therapy in combination with Abemaciclib (either NHI-reimbursed or self-funded), as determined by the primary treating physician. Prior chemotherapy requirement: Must have completed prior adjuvant chemotherapy at least 21 days before enrollment. All chemotherapy-related toxicities (except alopecia or Grade 2 peripheral neuropathy) must have resolved to ≤ Grade 1.\n\nD. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nE. Adequate bone marrow function as defined by:\n\n1. Absolute Neutrophil Count (ANC) ≥ 1,500\u002FμL without G-CSF support within 14 days of enrollment.\n2. Platelet count ≥ 100,000\u002FμL.\n3. Hemoglobin ≥ 8.0 g\u002FdL (red blood cell transfusion is permitted prior to enrollment).\n\nF. Adequate hepatic function, as defined by:\n\n1. Serum alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) ≤ 3× the upper limit of normal.\n2. Total bilirubin (T-bil) ≤ 1.5× the upper limit of normal. G. Willingness to refrain from using any other oral probiotics or prebiotics from the first dose of the study intervention (\"Synbiotic Supplement\" or placebo) through study completion.\n\nH. Ability to communicate with study personnel and willingness to comply with study visits, treatment plans, and other trial regulations.\n\nExclusion Criteria:\n\nA. Currently pregnant or breastfeeding. B. Received systemic antibiotic therapy for active viral, bacterial, or fungal infections within 2 weeks before the first dose of the study intervention.\n\nC. Severe pre-existing medical conditions that, in the investigator's judgment, preclude participation, including but not limited to the following:\n\n1. Severe renal impairment (e.g., estimated creatinine clearance \\\u003C 30 mL\u002Fmin).\n2. Interstitial lung disease.\n3. Severe dyspnea at rest or the requirement for oxygen therapy.\n4. History of major gastrointestinal surgeries, such as gastrectomy or small bowel resection.\n5. Pre-existing Crohn's disease, ulcerative colitis, or other chronic conditions that cause clinically significant diarrhea.\n\nD. History of the following cardiovascular conditions: syncope of cardiovascular origin, ventricular arrhythmias of pathological origin (including ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. Exception: Patients with atrial fibrillation that is controlled and stable for at least 30 days before randomization are eligible.\n\nE. Unwillingness or inability to provide written informed consent.","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study aims to evaluate whether the addition of probiotics can help reduce abdominal discomfort (such as diarrhea) in breast cancer patients receiving Abemaciclib treatment. Abemaciclib is an effective targeted therapy but often causes gastrointestinal side effects. While Loperamide is the standard treatment for diarrhea, this study explores if probiotics can provide additional relief and improve metabolic health.Participants will be randomly assigned to receive either probiotics or a placebo alongside their standard care. The study will monitor the frequency of abdominal symptoms and analyze blood samples to observe changes in metabolic factors.",[26,27],"Breast Cancer","Chemotherapy-induced Diarrhea","RECRUITING","2026-05-18",{"date":31,"type":32},"2026-05-26","ACTUAL",{"date":34,"type":20},"2026-05-15",{"date":36,"type":20},"2029-12-31",{"name":38,"class":39},"Leeuwenhoek Laboratories Co. Ltd.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":40},"100630538","phase-1-developing-microbial-therapy-for-masld-from-mechanism-to-clinical-validation-100630538","NCT07488975","Developing Microbial Therapy for MASLD: From Mechanism to Clinical Validation","Development of Microbial Therapeutics for Metabolic Dysfunction-Associated Steatotic Liver Disease: From Mechanistic Investigations to Clinical Trials","MASLD","Inclusion Criteria:\n\n* Fibroscan，CAP ≧ 260db\u002Fm\n\nExclusion Criteria:\n\nA. Pregnant women or women who are breastfeeding. B. Use of probiotics and prebiotic-related products (including yogurt, yogurt, Yakult, etc.) within 14 days before the screening visit.\n\nC. Patients who have used antibiotics (except skin lotions) or antifungal drugs within 30 days before the screening visit.\n\nD. Use of glucagon-like peptide-1 receptor agonists (GLP1-RAs) within six months prior to the screening visit.\n\nE. Use of drugs that may affect the evaluation index within 14 days before the screening visit, during the screening visit, or during the planned trial period, such as steroids, immunosuppressants, or anti-inflammatory drugs, or drugs containing ingredients for treating hepatitis or affecting fat metabolism, including HMG-CoA reductase inhibitors (statins), fibrates, silymarin, thiazolidinediones, metformin, cholestyramine, ezetimibe, orlistat, and sodium-glucose transporter type 2 inhibitors (SGLT2i). This restriction does not apply if the above-mentioned drugs have been used continuously for more than six months and the dosage is not changed during the trial.\n\nF. Those who have had severe gastrointestinal infection diarrhea symptoms within 14 days before the screening visit (more than three watery stools in 24 hours).\n\nG. Have the following medical history or laboratory abnormalities:","70 Years",{"count":51,"type":20},40,[53],"PHASE1","Metabolic dysfunction-associated steatotic liver disease (MASLD), redefined in 2020, is an improved diagnostic standard evolved from non-alcoholic fatty liver disease (NAFLD), emphasizing the correlation between hepatic steatosis and metabolic dysfunction. Compared to NAFLD, which relies on exclusion-based diagnosis, MASLD criteria enhance population homogeneity in studies and accommodate patients with coexisting liver diseases, thereby improving the efficiency and relevance of drug development. MASLD affects approximately one-quarter of the global population. If left untreated, it may progress to liver fibrosis, cirrhosis, or hepatocellular carcinoma. Given its high clinical burden and the current lack of FDA-approved therapies, effective treatments for MASLD are urgently needed.\n\nPrevious studies suggest that diet and gut microbiota play crucial roles in the pathogenesis of MASLD. Dietary composition influences microbial balance and intestinal barrier function. In dysbiosis, gut-derived harmful substances such as pathogen-associated molecular patterns (PAMPs) and microbiota-derived metabolites (MDMs) may translocate via a leaky gut to the liver through the portal vein, contributing to hepatic injury. These processes, often described as the gut-liver axis, remain incompletely understood.\n\nAnimal studies have shown that dietary components regulating gut microbiota may help alleviate MASLD. While clinical evidence remains limited, incorporating microbiota-modulating and immune-regulating food ingredients holds potential. Next-generation probiotics have demonstrated benefits in improving hepatic lipid metabolism and modulating gut microbiota, potentially slowing MASLD progression through gut-liver axis modulation.\n\nOur previous research investigated a pasteurized Akkermansia muciniphila strain, NTUH\\_Amuc03 (pAKK\\_LWHK0003), which attenuated fatty liver progression in preclinical models. In mice subjected to a high-fat, high-fructose, high-cholesterol diet, pAKK\\_LWHK0003 administration resulted in reduced body weight, improved dyslipidemia, lowered NAFLD activity scores, and improved HOMA-IR. These findings support the potential of pAKK\\_LWHK0003 in slowing MASLD progression.\n\nThis study aims to evaluate further the clinical efficacy and safety of pAKK\\_LWHK0003 in individuals with MASLD.",[56],"Metabolic Dysfunction-Associated Steatotic Liver Disease",[47,58],"MASH","2026-03-18",{"date":61,"type":32},"2026-03-23",{"date":63,"type":32},"2025-01-22",{"date":65,"type":20},"2026-12-31",{"name":38,"class":39},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":16,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":4},"100560514","phase-2-effects-of-synbiotics-on-obesity-100560514","NCT06578143","Effects of Synbiotics on Obesity","Effects of Synbiotics on Obesity and Obesity-related Parameters","Inclusion Criteria:\n\n* Age between 20-60 years.\n* Body weight ≥ 50 kg.\n* Body Mass Index (BMI) ≥ 24.\n* Body fat percentage ≥ 30% for females or ≥ 25% for males.\n* Waist circumference ≥ 80 cm for females or ≥ 90 cm for males.\n* No remarkable medical history within the past six months.\n* Willing to comply with the nutritional instructions during the study period.\n* Willing to report body weight once a week.\n* Willing to report dietary and activity records.\n* Willing to comply with the instruction of \"not using\" other products containing probiotics or enzymes (excluding yogurt and yogurt drinks).\n* Willing to sign Clinical Trial Informed Consent Form before the trial.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Without statutory notifiable diseases, including HIV, syphilis, hepatitis B, hepatitis C, etc.\n* Judged by a physician to have \"secondary obesity\" (obesity caused by endocrine disorders or metabolic abnormalities).\n* Presence of endocrine disorders, hypertension, diabetes, cerebrovascular diseases, cardiovascular diseases, liver diseases, kidney diseases, gastrointestinal diseases, or mental disorders.\n* Currently taking medications for lipid-lowering, blood sugar control, or weight loss.\n* Currently taking antibiotic-related medications.\n* Determined unsuitable for participation in this trial by a physician.",true,"20 Years","60 Years",{"count":19,"type":20},[23],"Synbiotics are a combination of probiotics and prebiotics that can promote the survival of probiotics in the gut. Probiotics utilize prebiotics to produce various metabolites beneficial to human health, such as short-chain fatty acids. The purpose of this trial is to evaluate the impact of a synbiotics product developed by Leewenhoek Laboratories Co., Ltd., on human obesity and its related biomarkers. Participants will be randomly assigned to either the experimental group or the control group in a double-blind trial. The intervention involves the experimental group taking the synbiotics product twice daily, two capsules per dose, after meals for six weeks. The control group will take an equal amount of placebo daily. During the trial, participants' body weight will be recorded weekly, and their body weight, waist circumference, hip circumference, body fat composition, and skeletal muscle mass will be measured before and after the intervention. Additionally, fasting blood samples and blood samples collected at 30, 60, 90, and 120 minutes after consuming the nutritional supplements will be analyzed. The study will compare body fat percentage, body weight, BMI, waist circumference, hip circumference, skeletal muscle mass, and obesity-related biomarkers in blood between the experimental and control groups. The trial results will be used to assess the efficacy of the synbiotics product in improving obesity and its related biomarkers.",[81],"Obesity","NOT_YET_RECRUITING","2024-10-07",{"date":85,"type":32},"2024-10-09",{"date":87,"type":20},"2024-10-15",{"date":89,"type":20},"2025-03-01",{"name":38,"class":39},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":74,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":100,"phases":4,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":4},"100544052","investigation-of-metabolomics-differences-between-metabolic-syndrome-and-healthy-individuals-in-taiwan-100544052","NCT06363864","Investigation of Metabolomics Differences Between Metabolic Syndrome and Healthy Individuals in Taiwan","Investigation of Metabolite Differences Between Taiwanese Metabolic Syndrome and Healthy Group Through Metabolomics","Inclusion Criteria:\n\n* Capable adults weigh ≥ 50 kg\n\nExclusion Criteria:\n\n* Not Taiwanese\n* Having received oral antibiotics, immunosuppressants, and chemotherapy drugs in the past month\n* Incapacity\n* Limited disposing capacity\n* Mental disorders or intellectual disabilities",{"count":99,"type":20},1200,"OBSERVATIONAL","The prevalence of metabolic syndrome in Taiwan has been increasing yearly. In this project, the database of blood test results from healthy and metabolic syndromes individuals will be analyzed to identify the small molecules related to the severity of metabolic syndrome. These identified small molecules could be used as biomarkers to predict the development of metabolic syndromes in the future.",[103],"Metabolic Syndrome","2024-04-09",{"date":106,"type":32},"2024-04-12",{"date":108,"type":20},"2024-04-14",{"date":110,"type":20},"2029-10-31",{"name":38,"class":39},""]